Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc. is a U.S.-based clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders. Its lead program is BNC210, an oral selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor being studied for social anxiety disorder and post-traumatic stress disorder, alongside earlier-stage CNS programs and partnered assets.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueBNC210 and other internal programs in discovery, preclinical, and clinical development.
Partnered programs with Merck targeting cognitive deficits in Alzheimer’s disease and other CNS conditions.
License revenue, milestone payments, and potential royalties from out-licensed intellectual property.
Customers
Neuphoria does not sell commercial medicines today; its direct counterparties are pharmaceutical partners, licensees, and research collaborators. If its programs succeed, the eventual end users are patients and prescribing clinicians in psychiatry and neurology, especially in anxiety, PTSD, and related CNS disorders.
Companies such as Merck that co-develop or license CNS programs and may fund development milestones.
Third parties developing licensed assets that can generate milestone and royalty income.
Psychiatrists, neurologists, and patients who would use approved BNC210-based therapies if commercialized.
Patients enrolled in SAD and PTSD studies who generate the clinical evidence base for the pipeline.
Strategy
Neuphoria’s strategy centers on advancing BNC210 through clinical development for SAD and PTSD while preserving optionality through partnerships and licensed programs. It also maintains value through collaboration economics, intellectual property rights, and broader strategic alternatives review activity.
Clinical proof-of-concept is the main path to value creation for the company.
Collaborations can provide external validation and non-dilutive economics.
The company is exploring paths that could maximize value beyond stand-alone development.
Geography
Neuphoria is headquartered in the United States and is now listed on Nasdaq in the U.S. Its development and partnering activities are global in scope, with historical roots in Australia and collaboration exposure that can extend across multiple jurisdictions through licensing and clinical development.
Risks
Neuphoria is a clinical-stage biopharmaceutical company with no approved products, so its value depends on successful trial outcomes, regulatory approval, and eventual commercialization. It also faces financing, partnership, and competition risks typical of drug developers, including the possibility that larger or faster-moving competitors reach the market first.
- Clinical failure of BNC210 or other pipeline assetsImpact: CriticalLikelihood: High
The company’s lead value driver is still in development and may not show efficacy or safety in later trials.
Exposure - Regulatory approval riskImpact: HighLikelihood: High
Even successful trials must satisfy FDA and other regulators, which can impose additional studies or restrictions.
Exposure: U.S. and foreign drug approvals
- Capital and dilution riskImpact: HighLikelihood: High
Clinical-stage biotechs often require external funding before any product revenue exists.
Exposure: Operating runway and development funding
- Competition in anxiety and PTSD therapiesImpact: HighLikelihood: Medium
Existing generics and emerging CNS programs may reach patients sooner or with better efficacy.
Exposure - Commercialization and partner dependenceImpact: MediumLikelihood: Low
If products are approved, the company may need third parties for sales, marketing, and distribution.
Exposure: Future product launch
Accounting
Judgemental itemsRevenue is recognized when contractual milestones are achieved, making results episodic and judgment-sensitive.
Impact: Can create large swings in reported revenue between periods
The company records changes in warrant fair value through earnings, affecting other income/loss.
Impact: Can materially change net loss without affecting cash
Government or other incentives can reduce net research expense when recognized.
Impact: Affects reported R&D spend and operating loss
Termination costs and lease-related impairments can be recognized during organizational changes.
Impact: Can increase operating expenses and reduce comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Neumora Therapeutics, Inc.
NMRA · Biological Products, (No Diagnostic Substances)
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Enveric Biosciences, Inc.
ENVB · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.\new
PTIX · Pharmaceutical Preparations
Protagenic Therapeutics, Inc.
NeOnc Technologies Holdings, Inc
NTHI · Pharmaceutical Preparations
Last updated: 24/09/2026